HomeCompareFGEN vs MCD

FGEN vs MCD: Dividend Comparison 2026

FGEN yields 22.05% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FGEN wins by $4.2K in total portfolio value
10 years
FGEN
FGEN
● Live price
22.05%
Share price
$9.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82.7K
Annual income
$8,340.12
Full FGEN calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — FGEN vs MCD

📍 FGEN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFGENMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FGEN + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FGEN pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FGEN
Annual income on $10K today (after 15% tax)
$1,874.31/yr
After 10yr DRIP, annual income (after tax)
$7,089.10/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, MCD beats the other by $15,204.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FGEN + MCD for your $10,000?

FGEN: 50%MCD: 50%
100% MCD50/50100% FGEN
Portfolio after 10yr
$80.6K
Annual income
$17,283.91/yr
Blended yield
21.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

FGEN
Analyst Ratings
5
Buy
7
Hold
2
Sell
Consensus: Hold
Price Target
$28.00
+208.7% upside vs current
Range: $28.00 — $28.00
Altman Z
-20.3
Piotroski
6/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FGEN buys
0
MCD buys
0
No recent congressional trades found for FGEN or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFGENMCD
Forward yield22.05%2.35%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$82.7K$78.5K
Annual income after 10y$8,340.12$26,227.70
Total dividends collected$49.4K$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy
Analyst price target$28.00$351.76

Year-by-year: FGEN vs MCD ($10,000, DRIP)

YearFGEN PortfolioFGEN Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$12,905$2,205.07$10,815$334.85+$2.1KFGEN
2$16,468$2,659.50$11,826$491.71+$4.6KFGEN
3$20,792$3,171.71$13,123$730.06+$7.7KFGEN
4$25,990$3,742.62$14,853$1,100.07+$11.1KFGEN
5$32,182$4,372.22$17,257$1,690.61+$14.9KFGEN
6$39,494$5,059.61$20,752$2,667.01+$18.7KFGEN
7$48,062$5,803.04$26,103$4,354.83+$22.0KFGEN
8$58,026$6,599.92$34,794$7,437.78+$23.2KFGEN
9$69,535$7,446.93$49,926$13,461.60+$19.6KFGEN
10$82,743$8,340.12$78,550$26,227.70+$4.2KFGEN

FGEN vs MCD: Complete Analysis 2026

FGENStock

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Full FGEN Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this FGEN vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FGEN vs SCHDFGEN vs JEPIFGEN vs OFGEN vs KOFGEN vs MAINFGEN vs YUMFGEN vs QSRFGEN vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.